Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients
Authors:
- Chul-Kee ParkCPChul-Kee Park
- JinWook KimJKJinWook Kim
- Su Youn YimSYSu Youn Yim
- Ah Reum LeeALAh Reum Lee
- Jung Ho HanJHJung Ho Han
- Chae-Yong KimCKChae-Yong Kim
- Sung-Hye ParkSPSung-Hye Park
- Tae Min KimTKTae Min Kim
- Se-Hoon LeeSLSe-Hoon Lee
- Seung Hong ChoiSCSeung Hong Choi
- Seung-Ki KimSKSeung-Ki Kim
- Dong Gyu KimDKDong Gyu Kim
Open Access
- 12 November 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (2) , 195-202
Abstract
Pseudoprogression is a major diagnostic dilemma in current treatment protocols for malignant gliomas that involve concurrent chemoradiotherapy. We hypothesized that methylation-specific multiplex ligation probe amplification (MS-MLPA), an assay that permits semiquantitative evaluation of promoter methylation, may be used to diagnose pseudoprogression based on the quantification of the methylation status of the O6-methylguanine DNA methyltransferase (MGMT) promoter. We examined the methylation ratio of the MGMT promoter with MS-MLPA in 48 samples from glioblastoma patients. The results were compared with those from methylation-specific polymerase chain reaction (MSP), and protein levels were confirmed by immunohistochemical staining. We then evaluated the correlation between those molecular signatures and clinical outcomes. With regard to radiological progression after chemoradiotherapy, the diagnostic accuracy of the MS-MLPA method was 80% (using a cut-off value of 0.2). These results are better than those obtained with MSP (diagnostic accuracy of 68%). Combining the MS-MLPA and MSP methods resulted in a diagnostic accuracy of 93% for the identification of pseudoprogression among patients to whom these results were coherent. These results demonstrate that MS-MLPA is a useful method to predict radiological progression vs pseudoprogression in glioblastoma patients and that the interpretation of these results in combination with MSP results will provide good practical guidelines for clinical decision making in glioblastoma treatment.Keywords
This publication has 22 references indexed in Scilit:
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nature Reviews Neurology, 2009
- Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant TemozolomideJournal of Clinical Oncology, 2007
- Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide TreatmentClinical Cancer Research, 2007
- Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant gliomaMolecular Cancer Therapeutics, 2006
- Multiplex Ligation-Dependent Probe AmplificationThe Journal of Molecular Diagnostics, 2006
- Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequencesNucleic Acids Research, 2005
- Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic GliomasClinical Cancer Research, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomasJournal of Neuro-Oncology, 2004
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990